Stock listing

Frankfurt:6UI Arecor Therapeutics PLC Aktie

German listing (Frankfurt) of Arecor Therapeutics PLC · home listing LSE:AREC

Follow Arecor Therapeutics PLC into a list and get an email when it puts out news.

Share price · FWB:6UI

€0.755 EUR -0.055 (-6.8%)

Close on Nov 20, 2026

Past year +39.4% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€0.680 – €0.775 EURNov 20, 2026
Market cap
€34.20M EURAt the close on Nov 20, 2026 · price × 45.30M shares outstanding
52-week range
€0.506 – €0.941 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
Arecor Therapeutics PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:AREC · Home71.50p GBX (pence)-6.00 (-7.7%)19,46576.00p76.38p70.00p77.50pClose on Nov 20, 2026
Frankfurt:6UI€0.755 EUR-0.055 (-6.8%)—€0.680€0.775€0.680€0.810Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:6UI · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.803-0.010-1.2%€0.697€0.804€0.6960
€0.813+0.006+0.7%€0.701€0.820€0.7000
€0.807-0.061-7.0%€0.739€0.865€0.7380
€0.868+0.009+1.0%€0.743€0.869€0.7420
€0.859+0.001+0.1%€0.747€0.860€0.7420
€0.858-0.009-1.0%€0.771€0.872€0.7600
€0.867+0.014+1.6%€0.747€0.867€0.7420
€0.853-0.004-0.5%€0.746€0.868€0.7400
€0.857+0.005+0.6%€0.747€0.871€0.7470
€0.852-0.003-0.4%€0.747€0.852€0.7440
€0.855+0.001+0.1%€0.744€0.860€0.7430
€0.854-0.005-0.6%€0.741€0.860€0.7390
€0.859+0.004+0.5%€0.746€0.861€0.7410
€0.855+0.007+0.8%€0.742€0.866€0.7420
€0.848-0.004-0.5%€0.738€0.856€0.7370
€0.852+0.001+0.1%€0.737€0.862€0.7370
€0.851+0.054+6.8%€0.730€0.861€0.7250
€0.797+0.049+6.6%€0.662€0.797€0.6600
€0.748+0.008+1.1%€0.667€0.749€0.6660
€0.740+0.003+0.4%€0.625€0.749€0.6240
€0.737+0.001+0.1%€0.645€0.743€0.6420
€0.736-0.009-1.2%€0.644€0.743€0.6400
€0.745+0.011+1.5%€0.642€0.745€0.6390
€0.734-0.002-0.3%€0.645€0.734€0.6350
€0.736+0.003+0.4%€0.646€0.747€0.6460
€0.7330.0000.0%€0.643€0.733€0.6400
€0.733+0.004+0.5%€0.640€0.742€0.6390
€0.729-0.176-19.4%€0.729€0.729€0.7290
€0.905-0.005-0.5%€0.783€0.909€0.7830
€0.910-0.003-0.3%€0.772€0.912€0.7690
€0.913+0.007+0.8%€0.774€0.919€0.7640
€0.906+0.001+0.1%€0.769€0.908€0.7670
€0.905+0.021+2.4%€0.772€0.907€0.7720
€0.884+0.001+0.1%€0.757€0.892€0.7560
€0.883+0.026+3.0%€0.755€0.884€0.7510
€0.857+0.007+0.8%€0.743€0.860€0.7430
€0.850+0.015+1.8%€0.758€0.861€0.7520
€0.835+0.031+3.9%€0.717€0.842€0.7130
€0.804+0.001+0.1%€0.708€0.811€0.7070
€0.803+0.003+0.4%€0.717€0.805€0.7160
€0.800+0.015+1.9%€0.673€0.806€0.6720
€0.785+0.001+0.1%€0.680€0.788€0.6770
€0.784+0.001+0.1%€0.681€0.789€0.6780
€0.783+0.005+0.6%€0.668€0.791€0.6660
€0.778+0.025+3.3%€0.671€0.783€0.6710
€0.753-0.002-0.3%€0.648€0.757€0.6430
€0.755-0.005-0.7%€0.644€0.757€0.6390
€0.760+0.002+0.3%€0.651€0.766€0.6500
€0.758+0.170+28.9%€0.651€0.758€0.6470
€0.588-0.135-18.7%€0.644€0.651€0.5800
€0.723+0.042+6.2%€0.598€0.724€0.5970
€0.681+0.001+0.1%€0.577€0.681€0.5740
€0.680+0.005+0.7%€0.583€0.685€0.5780
€0.675+0.123+22.3%€0.585€0.677€0.5810
€0.552-0.092-14.3%€0.552€0.552€0.5520
€0.644-0.011-1.7%€0.571€0.647€0.5710
€0.655+0.064+10.8%€0.549€0.656€0.5440
Ticker
Frankfurt:6UI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

Patents for concentrated ultra-rapid insulins

Oct 15, 2026

Closed €0.851 (+6.8%) on Oct 15, 2026

Holding(s) in Company

Oct 13, 2026

Closed €0.748 (+1.1%) on Oct 13, 2026

Half Year Results Investor Presentation

Oct 8, 2026

Closed €0.736 (-1.2%) on Oct 8, 2026

Result of Retail Offer

Oct 7, 2026

Closed €0.736 (-1.2%) on Oct 8, 2026

Retail Offer to raise up to £130,000

Sep 30, 2026

Closed €0.733 (+0.5%) on Oct 1, 2026

Results of Placing

Sep 30, 2026

Closed €0.729 (-19.4%) on Sep 30, 2026

Close of Accelerated Bookbuild to New Orders

Sep 30, 2026

Closed €0.729 (-19.4%) on Sep 30, 2026

AT278 data published in peer-reviewed journal

Aug 13, 2026

Closed €0.627 (+5.4%) on Aug 13, 2026

All Arecor Therapeutics PLC news

Arecor Therapeutics PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 155 in all · newest Oct 15, 2026 · oldest 2021
Calls
9 calls with a replay · 9 with a transcript · latest Oct 12, 2026
Decks
12 decks · latest Oct 12, 2026

Where Arecor Therapeutics PLC is listed

ListingExchangeCountryCurrency
LSE:AREC · Home listingLSEUnited KingdomGBX
LS Exchange:A3CRY2LS ExchangeGermanyEUR
Lang & Schwarz:A3CRY2Lang & SchwarzGermanyEUR
Dusseldorf:6UIDusseldorfGermanyEUR
Stuttgart:6UIStuttgartGermanyEUR
Frankfurt:6UI · This pageFrankfurtGermanyEUR

Valuation

EV/sales 17.1× against a median of 20.0×: 2nd lowest of 4 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
£29.29M GBP
P/E
48.8×
EV/sales
17.1×
EV/EBITDA
Negative EBITDA
Price/book
8.8×
Gross margin
61.3%
Operating margin
−272.2%
Net margin
38.7%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Arecor Therapeutics PLC · LSE:ARECUS$42.38MUS$38.33M48.8×17.1×n/a8.8×38.7%0.0×n/a
Spero Therapeutics, Inc. · NASDAQ:SPROUS$43.23M−US$63.10Mn/a−1.5×n/a55.4×−71.0%2.0×1.68
Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOXUS$43.15M−US$1.28Mn/an/an/a1.1×n/a0.3×n/a
Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBPUS$42.45M−US$68.98Mn/an/an/a0.5×n/a0.1×1.85
OS Therapies Incorporated · AMEX:OSTXUS$42.00MUS$41.57Mn/an/an/an/an/an/a1.70
Advagene Biopharma Co., Ltd. · TPEX:6709US$41.89MUS$32.03Mn/an/an/a3.9×n/a0.0×n/a
Biomea Fusion, Inc. · NASDAQ:BMEAUS$41.75MUS$15.85Mn/an/an/a5.5×n/a0.1×1.14
Prescient Therapeutics Limited · ASX:PTXUS$41.66MUS$35.82Mn/an/an/a4.4×n/a0.0×n/a
Mereo BioPharma Group plc · NASDAQ:MREOUS$41.52MUS$16.00Mn/a20.0×n/a1.8×n/a0.0×1.34
Elicio Therapeutics, Inc. · NASDAQ:ELTXUS$41.05MUS$19.78Mn/an/an/a2.2×n/a0.5×1.81
MiNK Therapeutics, Inc. · NASDAQ:INKTUS$40.93MUS$33.46Mn/a167×n/an/an/an/a0.81
Median of the othersUS$41.82MUS$17.89M20.0×3.0×−71.0%0.1×1.68

Forecasts

Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
250.50 GBX · Analysts' mean
EPS, year to Dec 2026
-0.13 · 2 analysts
Revenue, year to Dec 2026
300K · 2 analysts

Team and board

Officers

OfficerRole
Sarah HowellChief Executive Officer and Executive Director
David EllamChief Financial Officer and Executive Director
Arecor TherapeuticsSinger Capital Markets Advisory LLP
Phil DaviesSinger Capital Markets Advisory LLP
David GerringChief Development Officer
Jan JezekChief Scientific Officer

Board

DirectorRole
Andrew RichardsNon-Executive Chair and Chair of the Nomination Committee
David EllamChief Financial Officer and Executive Director
Jeremy MorganNon-Executive Director and Chair of the Remuneration Committee
Sam FazeliNon-Executive Director
Sarah HowellChief Executive Officer and Executive Director
Simon OrmistonNon-Executive Director and Chair of the Audit & Risk Committee

Events

Results days

QuarterResultsShare move
Q2 2025Sep 25, 2025+19.3%
Quarter to Mar 31, 2025May 6, 20250.0%
Q1 2023Apr 20, 2023 · Before open0.0%
Q2 2022Sep 8, 2022 · Before open0.0%
Q1 2022Apr 25, 2022 · Before open0.0%
Q2 2021Sep 23, 2021 · Before open+2.3%

Open Events

Decks

DeckKindSlidesDate
H1 2026 Earnings PresentationEarnings21 slidesOct 12, 2026
Investor Presentation (October 2026)Investor deck30 slidesOctober 2026
Investor Presentation (June 2026)Investor deck30 slidesJune 2026
FY2025 Earnings PresentationEarnings34 slidesApr 23, 2026
FY2025 Earnings PresentationEarnings34 slidesApr 13, 2026
FY2024 Earnings PresentationEarnings21 slidesApr 22, 2025
H1 2024 Earnings PresentationEarnings23 slidesSep 26, 2024
FY2023 Earnings PresentationEarnings25 slidesMay 16, 2024
H1 2023 Earnings PresentationEarnings22 slidesSep 14, 2023
FY2022 Earnings PresentationEarnings26 slidesApril 2023
All 12 decks
DeckKindSlidesDate
FY2021 Earnings PresentationEarnings23 slidesApr 25, 2022
H1 2021 Earnings PresentationEarnings21 slidesSep 23, 2021

Open Decks

Financings

RaiseDateIn US dollars
New ordinary shares (Retail Offer Shares)
Closed: £130,000 raised · GBX 68 a share · Singer Capital Markets +1
Dealers: Singer Capital Markets (lead), Singer Capital Markets Securities Limited
Use of proceeds: General working capital and to strengthen the Group's balance sheet
Oct 7, 2026US$171,735
Private placement of new ordinary shares
Update: about £5M · GBX 68 a share · Singer Capital Markets
Dealers: Singer Capital Markets (lead)
Use of proceeds: Strengthen balance sheet, extend cash runway to December 2027 and fund critical-path insulin development activities
Sep 30, 2026US$6.61M
Royalty financing with warrants over ordinary shares
Announced: up to US$11M · Warrants at GBX 67.39 for 120 months
Buyers: Ligand Pharmaceuticals Inc. (royalty financing of up to $11 million; warrants over 1,002,739 ordinary shares); Ligand (pays up to $11.0 million for royalty and fee rights and receives warrants over 1,002,739 ordinary shares); Ligand Pharmaceuticals Incorporated (pays up to $11.0 million for royalty rights and receives warrants over 1,002,739 ordinary shares)
Use of proceeds: Start AT278 Phase 2-enabling activities and extend cash runway to 1H 2027
Sep 25, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018
Revenue1.71M5.05M4.57M2.40M1.16M1.70M1.89M747.7K1.35M
Cost of revenue663.0K3.51M3.32M341.0K
Gross profit1.05M1.54M4.57M2.40M1.16M1.70M1.89M747.7K1.35M
Research and development2.69M3.04M5.98M8.61M5.39M3.94M3.56M3.09M2.33M
Selling, general and administrative3.17M6.18M8.91M5.55M2.39M1.64M1.61M1.42M1.00M
Operating income-4.67M-10.7M-9.18M-11.7M-5.98M-3.43M-2.69M-2.85M-1.40M
Depreciation and amortization215.0K446.0K496.0K341.0K171.0K168.0K151.5K166.9K172.9K
EBITDA-4.45M-10.3M-8.68M-11.3M-5.81M-3.26M-2.54M-2.69M-1.22M
Interest expense11.0K22.0K15.0K21.0K507.0K87.0K3.66K24.0K28.7K
Income before tax994.0K-10.6M-8.90M-10.5M-6.95M-3.51M-2.69M-2.87M-1.43M
Income tax62.0K-382.0K-347.0K-1.28M-776.0K-760.0K-502.3K-435.1K-307.0K
Net income664.0K-10.2M-8.55M-9.26M-6.17M-2.75M-2.19M-2.44M-1.12M
Earnings per share, basic0.02-0.31-0.28-0.32-0.27-0.10-0.08-0.09-0.04

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY2017
Cash and equivalents3.00M3.24M5.09M4.76M18.3M2.90M3.07M3.45M704.9K1.03M
Short-term investments3.13M18.0K1.66M8.04M
Receivables868.0K2.87M2.87M664.0K795.0K102.0K497.3K753.0K402.0K739.7K
Inventory0478.0K771.0K1.13M0-2071011.4K
Current assets7.00M8.23M11.2M17.5M20.5M3.82M3.92M5.00M1.52M1.90M
Property, plant and equipment838.0K328.0K375.3K295.1K353.1K438.5K551.7K
Goodwill01.48M1.48M0
Total assets8.10M8.72M15.4M21.8M20.9M4.28M4.31M5.45M2.07M2.56M
Accounts payable1.42M838.0K2.25M1.71M518.0K465.0K365.6K568.0K164.8K100.5K
Current liabilities1.61M3.26M5.15M3.73M2.27M1.41M1.04M1.11M823.3K958.6K
Long-term debt01.70M0351.8K
Total debt98.0K232.0K338.0K288.0K231.0K2.00M158.1K221.3K660.1K576.1K
Total liabilities1.65M3.37M5.85M4.31M2.37M3.51M1.10M1.23M1.40M1.23M
Shareholders' equity6.45M5.35M9.53M17.5M18.5M773.8K3.21M4.22M670.3K1.33M
Shares outstanding39.4M33.4M30.6M28.9M23.0M27.7M27.7M27.7M27.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018
Cash from operations-2.29M-9.15M-5.84M-10.8M-5.45M-1.86M-458.8K-2.50M-492.6K
Capital spending-99.0K-23.0K-151.0K-345.0K-69.0K-52.3K-32.3K-73.1K-12.9K
Free cash flow-2.39M-9.18M-5.99M-11.1M-5.52M-1.91M-491.1K-2.58M-505.5K
Cash from investing2.38M1.72M6.52M-7.99M-68.0K-49.3K-22.9K-64.6K-12.8K
Cash from financing-148.0K5.65M-180.0K5.16M20.9M1.77M-131.0K5.32M216.7K
Share buybacks4201.09K200.0K
Change in cash-238.0K-1.85M328.0K-13.6M15.4M-175.2K2.74M2.74M-323.4K

Open Financials

Cap table

Built by 6ix from Arecor Therapeutics PLC’s releases · as of Oct 7, 2026

Common shares
45,300,718
Fully diluted
45,300,718

Fully diluted

LineSharesAs of
Common shares45,300,718Oct 7, 2026

Share count over time

CountShares
Oct 7, 202645,300,718

Open Cap table

Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrew RichardsNon-Executive Chair and Chair of the Nomination Committee · Since at least Apr 13, 2026
Arecor TherapeuticsSinger Capital Markets Advisory LLP · Since at least Jan 6, 2026
David EllamChief Financial Officer and Executive Director · Since at least Oct 15, 2026
David GerringChief Development Officer · Since at least May 21, 2026
Jan JezekChief Scientific Officer · Since at least Oct 15, 2026
Jeremy MorganNon-Executive Director and Chair of the Remuneration Committee · Since at least Jun 2, 2025
Phil DaviesSinger Capital Markets Advisory LLP · Since at least Apr 28, 2026
Sam FazeliNon-Executive Director · Since at least Jun 2, 2025
Sarah HowellChief Executive Officer and Executive Director · Since at least Oct 15, 2026
Simon OrmistonNon-Executive Director and Chair of the Audit & Risk Committee · Since at least Sep 29, 2025

Open People

Log in to ask 6ix AI your own questions about Arecor Therapeutics PLC.